ADJUVANT PAZOPANIB OR PLACEBO IN RESECTED STAGE I NSCLC PATIENTS: RESULTS OF THE NSCLC ADJUVANT RANDOMIZED PHASE II TRIAL (IFCT-0703) FROM THE FRENCH COLLABORATIVE INTERGROUP

被引：0
|
作者：
Besse, Benjamin [1 ]
Mazieres, Julien [2 ]
Ribassin-Majed, L. [3 ]
Barlesi, Fabrice [4 ]
Bennouna, Jaafar [5 ]
Gervais, Radj [6 ]
Moreau, Lionel
Berard, Henri [7 ]
Debieuvre, Didier
Molinier, Olivier [8 ]
Moro-Sibilot, Denis [9 ]
Souquet, Pierre-Jean [10 ]
Pignon, Jean-Pierre [3 ]
Amour, Elodie [11 ]
Celebic, A. [3 ]
Morin, Franck [11 ]
Milleron, Bernard [11 ]
Zalcman, Gerard [12 ]
Soria, Jean-Charles [1 ]
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Univ Toulouse 3, Resp Med Serv, Hop Larrey, Chu Toulouse, F-31062 Toulouse, France
[3] Gustave Roussy, Biostat, Villejuif, France
[4] Aix Marseille Univ, Assistance Publ Hop Marseille, Marseille, France
[5] Inst Cancerol Ouest, Gustave Roussy, France
[6] Ctr Francois Baclesse, Caen, France
[7] Hop Instruct Armees St Anne, Serv Pathol Resp, Toulon, France
[8] Le Mans Reg Hosp, Le Mans, France
[9] Unite Oncol Thorac Pneumol, Pierre Benite, France
[10] Pneumol Hcl, Paris, France
[11] Ifct, Paris, France
[12] Caen Univ Hosp, Caen, France
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
adjuvant; Non small cell lung cancer; angiogenic inhibitor; randomized phase II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO08.02
引用
收藏
页码：S301 / S301
页数：1
相关论文
共 50 条
  • [1] Adjuvant pazopanib or placebo in resected stage I NSCLC patients: Results of the NSCLC adjuvant randomized phase II trial (IFCT0703) from the French collaborative Intergroup
    Besse, B.
    Mazieres, J.
    Pignon, J. P.
    Bennouna, J.
    Barlesi, F.
    Gervais, R.
    Amour, E.
    Morin, F.
    Zalcman, G.
    Soria, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S9 - S9
  • [2] Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
    Besse, B.
    Mazieres, J.
    Ribassin-Majed, L.
    Barlesi, F.
    Bennouna, J.
    Gervais, R.
    Moreau, L.
    Berard, H.
    Debieuvre, D.
    Molinier, O.
    Moro-Sibilot, D.
    Souquet, P. J.
    Jacquot, S.
    Petit, L.
    Lena, H.
    Pignon, J. P.
    Lacas, B.
    Morin, F.
    Milleron, B.
    Zalcman, G.
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1078 - 1083
  • [3] Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.
    Vasseur, Damien
    Jovelet, Cecile
    Cozic, Nathalie
    Mazieres, Julien
    Barlesi, Fabrice
    Bennouna, Jaafar
    Gervais, Radj
    Moreau, Lionel
    Berard, Henri
    Molinier, Olivier
    Moro-Sibilot, Denis
    Souquet, Pierre Jean
    Amour, Elodie
    Morin, Franck
    Zalcman, Gerard
    Soria, Jean-Charles
    Westeel, Virginie
    Lacroix, Ludovic
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Pazopanib (P) or placebo in completely resected stage I NSCLC patients: Survival results of the phase II trial IFCT-0703.
    Besse, Benjamin
    Mazieres, Julien
    Ribassin-Majed, Laureen
    Barlesi, Fabrice
    Bennouna, Jaafar
    Gervais, Radj
    Moreau, Lionel
    Berard, Henri
    Debieuvre, Didier
    Molinier, Oliver
    Moro-Sibilot, Denis
    Souquet, Pierre Jean
    Pignon, Jean-Pierre
    Amour, Elodie
    Celebic, Aljosa
    Morin, Franck
    Milleron, Bernard
    Zalcman, Gerard
    Soria, Jean-Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] ADJUVANT CISPLATINUM-DOCETAXEL CHEMOTHERAPY IN STAGE IB-II RESECTED NSCLC PATIENTS: THE TOLEDO TRIAL
    Bosquee, L.
    Germonprez, P.
    Aerts, J.
    Peters, F.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S52 - S53
  • [6] A phase II study of gemcitabine plus carboplatin as adjuvant chemotherapy in patients with resected NSCLC
    Yoshino, Reiko
    Tomizawa, Yoshio
    Takei, Kousuke
    Tomizawa, Mai
    Yoshii, Akihiro
    Kawashima, Osamu
    Watanabe, Satoru
    Hisada, Takeshi
    Saitou, Ryusei
    Yamada, Masanobu
    ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [7] The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
    Heymach, J.
    Taube, J.
    Mitsudomi, T.
    Harpole, D.
    Aperghis, M.
    Trani, L.
    Powell, M.
    Dennis, P.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S625 - S626
  • [8] Randomized phase II study of adjuvant afatinib for three months versus two years in patients with resected stage I-III EGFR mutant NSCLC.
    Chaft, Jamie E.
    Costa, Daniel Botelho
    Muzikansky, Alona
    Shrager, Joseph B.
    Lanuti, Michael
    Huang, James
    Ramchandran, Kavitha
    Rangachari, Deepa
    Huberman, Mark
    Piotrowska, Zofia
    Kris, Mark G.
    Azzoli, Christopher G.
    Sequist, Lecia V.
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] Osimertinib as adjuvant therapy in patients with resected EGFRm stage IB-IIIA NSCLC: updated results from ADAURA
    Grohe, C.
    Tsuboi, M.
    Wu, Y.
    John, T.
    Majem, M.
    Wang, J.
    Kato, T.
    Goldman, J.
    Kim, S.
    Yu, C.
    Vu, H.
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F.
    Urban, D.
    Stachowiak, M.
    Balanos, A.
    Huang, X.
    Herbst, R.
    Kern, J.
    PNEUMOLOGIE, 2023, 77 : S17 - S17
  • [10] SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
    Pennell, Nathan A.
    Neal, Joel W.
    Chaft, Jamie E.
    Azzoli, Christopher G.
    Janne, Pasi A.
    Govindan, Ramaswamy
    Evans, Tracey L.
    Costa, Daniel Botelho
    Rosovsky, Rachel Pam Greenerger
    Wakelee, Heather A.
    Heist, Rebecca Suk
    Shaw, Alice Tsang
    Temel, Jennifer S.
    Shapiro, Marc A.
    Muzikansky, Alona
    Lanuti, Michael
    Lynch, Thomas James
    Kris, Mark G.
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345